202 related articles for article (PubMed ID: 15134534)
1. Leukotriene A4 hydrolase as a target for cancer prevention and therapy.
Chen X; Wang S; Wu N; Yang CS
Curr Cancer Drug Targets; 2004 May; 4(3):267-83. PubMed ID: 15134534
[TBL] [Abstract][Full Text] [Related]
2. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin.
Chen X; Li N; Wang S; Wu N; Hong J; Jiao X; Krasna MJ; Beer DG; Yang CS
J Natl Cancer Inst; 2003 Jul; 95(14):1053-61. PubMed ID: 12865451
[TBL] [Abstract][Full Text] [Related]
3. Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.
Audat SA; Al-Shar'i NA; Al-Oudat BA; Bryant-Friedrich A; Bedi MF; Zayed AL; Al-Balas QA
Molecules; 2020 Jun; 25(12):. PubMed ID: 32580506
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of LTA4H by bestatin in human and mouse colorectal cancer.
Zhao S; Yao K; Li D; Liu K; Jin G; Yan M; Wu Q; Chen H; Shin SH; Bai R; Wang G; Bode AM; Dong Z; Guo Z; Dong Z
EBioMedicine; 2019 Jun; 44():361-374. PubMed ID: 31085102
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.
Numao S; Hasler F; Laguerre C; Srinivas H; Wack N; Jäger P; Schmid A; Osmont A; Röthlisberger P; Houguenade J; Bergsdorf C; Dawson J; Carte N; Hofmann A; Markert C; Hardaker L; Billich A; Wolf RM; Penno CA; Bollbuck B; Miltz W; Röhn TA
Sci Rep; 2017 Oct; 7(1):13591. PubMed ID: 29051536
[TBL] [Abstract][Full Text] [Related]
6. Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase.
Fourie AM
Curr Opin Investig Drugs; 2009 Nov; 10(11):1173-82. PubMed ID: 19876785
[TBL] [Abstract][Full Text] [Related]
7. The leukotriene B
Deng B; Lin Y; Ma S; Zheng Y; Yang X; Li B; Yu W; Xu Q; Liu T; Hao C; He R; Ding F
Kidney Int; 2017 Jul; 92(1):89-100. PubMed ID: 28318626
[TBL] [Abstract][Full Text] [Related]
8. Binding of Pro-Gly-Pro at the active site of leukotriene A4 hydrolase/aminopeptidase and development of an epoxide hydrolase selective inhibitor.
Stsiapanava A; Olsson U; Wan M; Kleinschmidt T; Rutishauser D; Zubarev RA; Samuelsson B; Rinaldo-Matthis A; Haeggström JZ
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4227-32. PubMed ID: 24591641
[TBL] [Abstract][Full Text] [Related]
9. The development of novel LTA
Low CM; Akthar S; Patel DF; Löser S; Wong CT; Jackson PL; Blalock JE; Hare SA; Lloyd CM; Snelgrove RJ
Sci Rep; 2017 Mar; 7():44449. PubMed ID: 28303931
[TBL] [Abstract][Full Text] [Related]
10. Leukotriene A4 hydrolase: an emerging target of natural products for cancer chemoprevention and chemotherapy.
Vo TTL; Jang WJ; Jeong CH
Ann N Y Acad Sci; 2018 Nov; 1431(1):3-13. PubMed ID: 30058075
[TBL] [Abstract][Full Text] [Related]
11. A sensitive fluorigenic substrate for selective in vitro and in vivo assay of leukotriene A4 hydrolase activity.
Poras H; Duquesnoy S; Fournié-Zaluski MC; Ratinaud-Giraud C; Roques BP; Ouimet T
Anal Biochem; 2013 Oct; 441(2):152-61. PubMed ID: 23851339
[TBL] [Abstract][Full Text] [Related]
12. Classification and QSAR models of leukotriene A4 hydrolase (LTA4H) inhibitors by machine learning methods.
Qin R; Wang H; Yan A
SAR QSAR Environ Res; 2021 May; 32(5):411-431. PubMed ID: 33896285
[TBL] [Abstract][Full Text] [Related]
13. Gliotoxin from Aspergillus fumigatus Abrogates Leukotriene B
König S; Pace S; Pein H; Heinekamp T; Kramer J; Romp E; Straßburger M; Troisi F; Proschak A; Dworschak J; Scherlach K; Rossi A; Sautebin L; Haeggström JZ; Hertweck C; Brakhage AA; Gerstmeier J; Proschak E; Werz O
Cell Chem Biol; 2019 Apr; 26(4):524-534.e5. PubMed ID: 30745237
[TBL] [Abstract][Full Text] [Related]
14. Role of leukotriene A4 hydrolase aminopeptidase in the pathogenesis of emphysema.
Paige M; Wang K; Burdick M; Park S; Cha J; Jeffery E; Sherman N; Shim YM
J Immunol; 2014 Jun; 192(11):5059-68. PubMed ID: 24771855
[TBL] [Abstract][Full Text] [Related]
15. Dual anti-inflammatory and selective inhibition mechanism of leukotriene A4 hydrolase/aminopeptidase: insights from comparative molecular dynamics and binding free energy analyses.
Appiah-Kubi P; Soliman ME
J Biomol Struct Dyn; 2016 Nov; 34(11):2418-33. PubMed ID: 26555301
[TBL] [Abstract][Full Text] [Related]
16. Capturing LTA
Stsiapanava A; Samuelsson B; Haeggström JZ
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9689-9694. PubMed ID: 28827365
[TBL] [Abstract][Full Text] [Related]
17. Development of a homogeneous time-resolved fluorescence leukotriene B4 assay for determining the activity of leukotriene A4 hydrolase.
Liang AM; Claret E; Ouled-Diaf J; Jean A; Vogel D; Light DR; Jones SW; Guilford WJ; Parkinson JF; Snider RM
J Biomol Screen; 2007 Jun; 12(4):536-45. PubMed ID: 17384330
[TBL] [Abstract][Full Text] [Related]
18. Leukotriene A4 hydrolase: selective abrogation of leukotriene B4 formation by mutation of aspartic acid 375.
Rudberg PC; Tholander F; Thunnissen MM; Samuelsson B; Haeggstrom JZ
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4215-20. PubMed ID: 11917124
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, docking, cytotoxicity, and LTA
El-Naggar MH; Mira A; Abdel Bar FM; Shimizu K; Amer MM; Badria FA
Bioorg Med Chem; 2017 Feb; 25(3):1277-1285. PubMed ID: 28065501
[TBL] [Abstract][Full Text] [Related]
20. Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.
Appiah-Kubi P; Soliman M
Cell Biochem Biophys; 2017 Mar; 75(1):35-48. PubMed ID: 27914004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
